Journals / Haseki Tıp Bülteni / 2012 / Cilt: 50 - Sayı: 2

Relationship between plasma homocystein levels and polyneuropaty in patients using levodopa for ıdiopathic parkinson’s disease

Levodopa kullanmakta olan idiyopatik parkinson hastalarında plazma homosistein düzeyi ve polinöropati ilişkisi

Pages
53–58
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Although in our study, we did not show any correlation between polyneuropathy and high plasma homocysteine levels, further studies including homogeneous groups of younger patients with PD are needed. (The Medical Bulletin of Hase ki 2012; 50: 53-8)

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Recent studies showed high plasma homocysteine levels in patients treated with Levodopa for Parkinson’s disease (PD).
📊
Key Findings & Data:Material and Methods: Forty-one patients with PD receiving levodopa treatment (patient group) and 30 healthy subjects (control group) were included in this study.
💡
Conclusion & Impact:Conclusion: Although in our study, we did not show any correlation between polyneuropathy and high plasma homocysteine levels, further studies including homogeneous groups of younger patients with PD are needed. (The Medical Bulletin of Hase ki 2012; 50: 53-8)
🔬Design:Research Article
📍Scope:2012 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: Recent studies showed high plasma homocysteine levels in patients treated with Levodopa for Parkinson’s disease (PD). Homocysteine, due to its exotoxic effect, might be the cause of polyneuropathy seen in PD. In this study, our aim was to show the correlation between high concentration of plasma homocysteine levels and polyneuropathy associated with PD.. Material and Methods: Forty-one patients with PD receiving levodopa treatment (patient group) and 30 healthy subjects (control group) were included in this study. We compared the two groups in terms of electrophysiological findings. Twelve patients had high plasma homocysteine levels and 29 of them had low plasma homocysteine levels. Results: Six of the 41 patients had sensorial polyneuropathy and decreased compound muscle action potantiel amplitude compared to controls. Two patients had high plasma homocysteine levels, two patients had nearly high plasma homocysteine levels, two patients had low plasma homocysteine levels who had sensorial polyneuropathy. Conclusion: Although in our study, we did not show any correlation between polyneuropathy and high plasma homocysteine levels, further studies including homogeneous groups of younger patients with PD are needed. (The Medical Bulletin of Hase ki 2012; 50: 53-8)

Özet

Amaç: Son yıllarda levodopa kullanan idiyopatik Parkinson hastalarında plazma homosistein düzeyinin, normal bireylere ve levodopa kullanmayan Parkinson hastalarına göre daha yüksek olduğu saptanmıştır. Homosisteinin eksotoksik etkisinin Parkinson hastalığında görülen polinöropatinin bir nedeni olabileceği de tartışılmaktadır. Araştırmamızda idiyopatik Parkinson hastalarında plazma homosistein düzeyi bakılarak, plazma homosistein düzeyi normal ve yüksek bulunan gruplar ile kontrol grubunun elektrofizyolojik özelliklerinin (motor ve duysal ileti çalışmaları) karşılaştırılması amaçlanmıştır. Yöntem ve Gereç: Çalışmamıza polikliniğimizden takipli idiyopatik Parkinson hastalığı (İPH) tanı kriterlerini dolduran, polinöropatiye neden olabilecek ikincil bir hastalığı bulunmayan ve hepsi levodopa kullanan 41 hasta ve yaş uyumlu, sağlıklı 30 birey, duysal ve motor iletileri açısından elektrofizyolojik olarak karşılaştırıldı. Bulgular: Kırk bir hastanın altısında duyusal lifleri tutan polinöropati ve düşük bileşik kas aksiyon potansiyelleri saptandı. Duyusal polinöropati saptanan hastaların ikisinde homosistein düzeyi yüksek, ikisinde normalin üst sınırında, ikisinde ise düşük saptandı. Sonuç: Çalışmamızda polinöropati sıklığında artış ile homosistein yüksekliği arasında anlamlı birliktelik saptanmasa da ileri çalışmaların daha homojen ve genç hasta gruplarında yapılmasına ihtiyaç vardır.

🔖

Cite This Article

BEDİR, M., HÜRTAN, A., ÖZER, F., ATMACA, B. K., MUTLU, A., GENÇ, F., ÖZBEN, S., KOLTAŞ, M., AYDEMİR, T. Ö., PETEK, B. B. (2012). Relationship between plasma homocystein levels and polyneuropaty in patients using levodopa for ıdiopathic parkinson’s disease. Haseki Tıp Bülteni, Cilt: 50 - Sayı: 2, 53–58. https://ajindex.com/articles/268003

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Blandini F, Fancellu R, Martignoni E, et al. Plasma homocysteine and L-dopa metabolism in patients with Parkinson disease. Clin Chem 2001;47:1102–4
  2. Rogers JD, Sanchez-Saffon A, Frol AB, Diaz-Arrastia R. Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease. Arch Neurol 2003;60:59–64
  3. Yasui K, Kowa H, Nakaso K, Takeshima T, Nakashima K. Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology 2000;55:437–40
  4. Kuhn W, Roebroek R, Blom H, Van Oppenraaij D, Muller T. Hyperhomocysteinaemia in Parkinson’s disease. J Neurol 1998;245:811–2
  5. Kuhn W, Roebroek R, Blom H, et al. Elevated plasma levels of homocysteine in Parkinson’s disease. Eur Neurol 1998;40:225–7
  6. Miller JW, Shukitt-Hale B, Villalobos-Molina R, Nadeau MR, Selhub J, Joseph JA. Effect of L-Dopa and the catechol-O-methyltransferase inhibitor Ro 41-0960 on sulfur amino acid metabolites in rats. Clin Neuropharmacol 1997;20:55–66
  7. Clarke S, Banfield K. S-adenosylmethionine-dependent methyltransferases. In Carmel R, Jacobsen DW editors. Homocysteine in health and disease. New York: Cambridge University Pres; 2001. p. 63–78
  8. Brosnan JT, Jacobs RL, Stead LM, Brosnan ME. Methylation demand: a key determinant of homocysteine metabolism. Acta Biochim Pol 2004;51:405-13
  9. Goyette P, Frosst P, Rosenblatt DS, Rozen R. Seven novel mutations in the methylenetetrahydrofolate reductase gene and genotype/phenotype correlations in severe methylenetetrahydrofolate reductase deficiency. Am J Hum Genet 1995;56:1052-9
  10. Miller JW, Selhub J, Nadeau MR, Thomas CA, Feldman RG, Wolf PA. Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status. Neurology 2003;60:1125–9
  11. Nissinen E, Nissinen H, Larjonmaa H, et al. The COMT inhibitor entacapone, reduces levodopa- induced elevations in plasma homocysteine in heathy adult rats. J Neural Transm 2005;112:1213-21. Epub 2004 Dec 22
  12. Snow CF. Laboratory diagnosis of vitamin B12 and folate deficiency: a guide for the primary care physician. Arch Intern Med 1999;159:1289–98
  13. Lamberti P, Zoccolella S, Armenise E, et al. Hyperhomocysteinemia in L-dopa treated Parkinson’s disease patients: effect of cobalamin and folate administration. Eur J Neurol 2005;12:365–8
  14. Zoccolella S, Lamberti P, Armenise E, et al. Plasma homocysteine levels in Parkinson’s disease: role of antiparkinsonian medications. Parkinsonism Relat Disord 2005;11:13